Скачать или смотреть Commercializing Transformative Therapies for Blindness Diseases - Ocugen, Inc. (NASDAQ: OCGN)

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform is a cutting-edge technology licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School) and involves targeted delivery and expression of one or more nuclear hormone receptor genes in the disease tissues with the potential to treat multiple retinal diseases with one drug – “one to many.” OCU400 (AAV-NR2E3) is a novel gene therapy product candidate with the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases. OCU410 (AAV-RORA) is a modifier gene therapy product candidate being developed for the treatment of dry age-related macular degeneration. OCU200 is a biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema, Diabetic Retinopathy, and Wet Age-Related Macular Degeneration.

For more information about the company please visit https://ocugen.com/

Corporate Speaker:

Shankar Musunuri, PhD, MBA, Chairman of the Board, CEO and Co-Founder

Shankar Musunuri, PhD, MBA is Chairman of the Board, CEO and Co-Founder of Ocugen, Inc. Dr. Musunuri is a seasoned biotech veteran with more than 25 years of results-driven experience advancing and commercializing a diverse portfolio of products. Prior to co-founding Ocugen in 2013, Dr. Musunuri held leadership roles at numerous companies ranging from “Big Pharma” to novel start-up biotechs. Most recently, he founded Nuron Biotech, Inc., which he grew to a commercial company in less than three years, serving as President and CEO. Dr. Musunuri obtained his PhD in Pharmaceutical Sciences from the University of Connecticut and an MBA from Duke University’s Fuqua School of Business. Dr. Musunuri is a thought leader sharing his insights on gene therapy including the areas of strategic partnerships, regulatory review, and reimbursement strategy.

Disclaimer: NAI is being compensated for this content. Materials contained in this content are for information purposes only and is not intended to constitute an offering of securities in any jurisdiction. Nothing on this content should be construed as an offer, solicitation or recommendation to buy or sell products or securities.

0:09 Ocugen Overview
4:50 Experienced Leadership Team
5:52 Pipeline Overview
7:10 Traditional Approaches vs. Ocugen's Novel Platform
9:24 Why Target Nuclear Hormone Receptor Genes (NHRs)?
10:42 OCU400 - Rescue in Early & Advanced Stage of Disease
14:41 OCU410 (AAV-RORA) - Dry Age-Related Macular Degeneration
15:26 Gene Therapy Manufacturing
17:07 OCU200 - Novel Biologic Offering Benefits Beyond Anti-VEGF
20:02 Near & Mid-Term Milestones: Planned Timeline
21:13 Capital Structure Summary
21:37 Investment Highlights


Music: https://www.bensound.com/royalty-free

【Stay Connected! 】
Website: https://nai500.com
Twitter: @NAI500
LinkedIn: NAI Interactive Ltd
Facebook: @naigcff
Join us at an upcoming event! http://www.gcff.ca/

Copyright © 2020 NAI Interactive Ltd. All rights reserved.